CoChat

Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Treatment of severe hypoglycemia outside of the hospital setting is limited to glucagon formulations requiring reconstitution before use, which may lead to erroneous or delayed glucagon administration. We compared the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics and safety and tolerability of different doses of dasiglucagon, a novel soluble glucagon analog, with approved pediatric and full doses of GlucaGen in insulin-induced hypoglycemia in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion. RESULTS: Dasiglucagon demonstrated a dose-dependent and rapid increase in plasma concentrations, reaching a maximum at ∼35 min with a half-life of ∼0.5 h. Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9–14 min) to PG ≥70 mg/dL (within 6–10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG. All patients on both treatments reached these end points within 30 min (predefined success criteria). Both treatments were well tolerated. Nausea was the most frequent adverse event, occurring at a similar rate (44–56%). CONCLUSIONS: Dasiglucagon was well tolerated and showed an early PD response similar to that of GlucaGen at corresponding doses, suggesting comparable clinical effects of the two glucagon formulations. Dasiglucagon has the potential to become an effective and reliable rescue treatment for severe hypoglycemia in a ready-to-use pen.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc17-1402

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 116

Metadata

Authors
Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T.
Affiliations
  • Profil Institute for Metabolic Research (DE)
  • Zealand Pharma (Denmark) (DK)
Corresponding author
Hövelmann, Ulrike
Venue
Diabetes Care
Published
2017-12-22
Volume
41
Issue
3
Pages
531-537
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2781395153
Cited by
115
References
26
Citations by year
2026: 8 · 2025: 9 · 2024: 7 · 2023: 17 · 2022: 18 · 2021: 26 · 2020: 7 · 2019: 15 · 2018: 6
FWCI
6.05
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
Keywords
dasiglucagon, glucagon analog, severe hypoglycemia, type 1 diabetes, insulin-induced hypoglycemia, pharmacokinetics, pharmacodynamics, subcutaneous injection, salvage therapy, glycemic response, nausea, drug safety and tolerability
MeSH terms
Adolescent, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glucagon, Half-Life, Humans, Hypoglycemia, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. https://app.cochat.ai/papers/10.2337/dc17-1402
The paper
Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T. (2018). Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care. https://doi.org/10.2337/dc17-1402

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.